Inside Trade

November 3, 2025

FTA Central

Senate Ag Committee Dems Push Froman For Better Dairy Access In TPP

Seven Democratic members of the Senate Agriculture Committee have pushed U.S. Trade Representative Michael Froman to extract sufficient market access for U.S. dairy products in Canada and Japan under the Trans-Pacific Partnership (TPP) that would offset market share gains New Zealand may secure from the pact. In a letter sent to Froman on Oct. 2, the senators specifically accuse Canada and Japan of being “reluctant players” in the dairy negotiations over the years of the TPP talks, and reference New...

Froman, Robb Meet On IP Ahead Of CN Meeting, Ministerial Plenary

ATLANTA -- U.S. Trade Representative Michael Froman and Australian Minister for Trade and Investment Andrew Robb on Friday afternoon (Oct. 2) were holding a bilateral meeting to discuss the controversial issue of the exclusivity term for biologics drugs, in what could be a pivotal moment for whether a broader Trans-Pacific Partnership (TPP) deal comes together here. Froman and Robb were meeting ahead of ministerial plenary session slated for roughly 6:30 p.m. local time, to be preceded by a meeting of...

Levin Says 'May 10' Applies To Biologics, Signals Opposition To '5+3'

ATLANTA -- House Ways & Means Committee Ranking Member Sander Levin (D-MI) on Friday (Oct. 2) strongly signaled that he opposes the new U.S. proposal for an eight-year market exclusivity term for biologics drugs in the Trans-Pacific Partnership (TPP) because it goes beyond the so-called “May 10” agreement that he negotiated with the George W. Bush administration. Levin argued that the May 10 deal provided for five years of data exclusivity for all drugs, including biologics. “As it's discussed, I...

Eli Lilly Rebukes Canadian Government Response In NAFTA Pharma Patent Dispute

Eli Lilly And Company Reply Memorial

Government Of Canada Counter Memorial

Previously Posted:
Canadian High Court Takes Up Drug Patent Case, Delaying Legal Changes

150281

DeLauro, Schakowsky, AARP Blast USTR's '5+3' Data Exclusivity Biologics Proposal

Editor's Note: A spokesperson from Representative Rosa DeLauro's (D-CT) clarified that DeLauro's press release is a response to a proposal for 5+3 years of data exclusivity for biologics tabled by U.S. trade negotiators at the ongoing TPP negotiations in Atlanta and is not a response to an agreement reached by all TPP members.

DeLauro Press Release

Rep. Jan Shakowsky Press Release

150280

21 House Dems, Health Groups Urge Froman To Press For Tobacco Carveout In Final TPP Deal

Editor's Note: This letter was originally signed by 10 House Democrats. The original signatories were Reps. Ami Bera (D-CA), Jared Polis (D-CO), Ron Kind (D-WI), Sam Farr (D-CA), Susan Davis (D-CA), Earl Blumenauer (D-OR), Donald Beyer (D-VA), Beto O'Rourke (D-TX), Suzanne Bonamici (D-OR), Derek Kilmer (D-WA) and Mike Quigley (D-IL).

150276

Obama, Turnbull Discuss TPP Over Phone, White House Announces

White House Readout Of President Obama's Phone Call With Australian Prime Minister Malcolm Turnbull

Previously Posted:
Obama Pushes For Flexibility On Key Issues In Calls With TPP Leaders

150274

21 Canadian Industry, Farm Groups Press For Swift TPP Conclusion

Editor's Note: This statement is from the following organizations: Canadian Chamber of Commerce, Canadian Manufacturers and Exporters, Canadian Council of Chief Executives, Canadian Services Coalition, Canadian Intellectual Property Council, I.E.

150272

Malmstrom Meets With Belgian Regional Official Over TTIP, Touts New Investment Court Proposal

European Commission Press Release

Previously Posted:
Malmstrom Touts New EU ISDS Model; Says TTIP Will Aid Progress On Global Trade Agreements

150270

U.S. Formally Tables '5+3' Years Exclusivity Period For Biologics Drugs

ATLANTA -- The United States has formally tabled here to other Trans-Pacific Partnership (TPP) countries a proposal that would require parties to grant five years of data exclusivity for biologics drugs and impose an additional three years of "post-market surveillance," in the first official sign that it is willing to drop its 12-year market exclusivity demand. But other countries such as Chile and Peru point out that the proposal will still keep generic biologic drugs off the market for a...

Not a subscriber?

Request 30 days free access to exclusive, behind-the-scenes reporting on trade policy in the Trump era.